创新链/学科链/研发链/产业链

新药研发前沿动态 / 医药领域趋势进展

王慧, 丁选胜. 糖尿病心肌病治疗药物研究进展[J]. 药学进展, 2018, 42(11): 860-867.
引用本文: 王慧, 丁选胜. 糖尿病心肌病治疗药物研究进展[J]. 药学进展, 2018, 42(11): 860-867.
WANG Hui, DING Xuansheng. Research Progress in Therapeutic Drugs for Diabetic Cardiomyopathy[J]. Progress in Pharmaceutical Sciences, 2018, 42(11): 860-867.
Citation: WANG Hui, DING Xuansheng. Research Progress in Therapeutic Drugs for Diabetic Cardiomyopathy[J]. Progress in Pharmaceutical Sciences, 2018, 42(11): 860-867.

糖尿病心肌病治疗药物研究进展

Research Progress in Therapeutic Drugs for Diabetic Cardiomyopathy

  • 摘要: 糖尿病心肌病(DCM)是糖尿病主要并发症之一,是独立于高血压性心脏病、冠状动脉粥样硬化性心脏病、心脏瓣膜病及其他已知心脏疾病的心脏特异性病变,最终进展可致患者心力衰竭和死亡。因此,DCM的治疗药物备受关注,将从西药和中药2个方面对DCM的治疗药物研究进展进行综述,以期为临床提供参考。

     

    Abstract: Diabetic cardiomyopathy (DCM) is one of the major complications of diabetes. It is a unique set of heart-specific pathological variables in diabetic patients, independent of hypertensive heart disease, coronary atherosclerotic heart disease, valvular heart disease and other heart diseases. The final progress of DCM can lead to heart failure and death. Therefore, the treatment of DCM has attracted increased attention. The research progress in therapeutic drugs for DCM was reviewed from the aspects of western medicine and traditional Chinese medicine, so as to provide reference for clinical treatment.

     

/

返回文章
返回